Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide effect on hypoglycemia counter-regulatory response
NCT04050553Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2020
- Primary completion
- Jan 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Tirzepatide with Placebo (2 arms). Primary endpoint: Change in Mean Glucagon Concentration During Induced Hypoglycemia at Week 12. Started Feb 2020; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04050553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04050553.